- Home
- LZ vs MESO Comparison
LZ vs MESO Comparison
Compare LZ & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LZ
- MESO
- Stock Information
- Founded
- LZ 2001
- MESO 2004
- Country
- LZ United States
- MESO Australia
- Employees
- LZ N/A
- MESO N/A
- Industry
- LZ EDP Services
- MESO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LZ Technology
- MESO Health Care
- Exchange
- LZ Nasdaq
- MESO Nasdaq
- Market Cap
- LZ 1.8B
- MESO 1.4B
- IPO Year
- LZ 2021
- MESO N/A
- Fundamental
- Price
- LZ $9.13
- MESO $10.64
- Analyst Decision
- LZ Hold
- MESO Buy
- Analyst Count
- LZ 9
- MESO 4
- Target Price
- LZ $8.64
- MESO $18.00
- AVG Volume (30 Days)
- LZ 2.3M
- MESO 226.6K
- Earning Date
- LZ 05-07-2025
- MESO 02-26-2025
- Dividend Yield
- LZ N/A
- MESO N/A
- EPS Growth
- LZ 72.11
- MESO N/A
- EPS
- LZ 0.17
- MESO N/A
- Revenue
- LZ $690,777,000.00
- MESO $5,670,000.00
- Revenue This Year
- LZ $8.12
- MESO $178.09
- Revenue Next Year
- LZ $6.66
- MESO $305.06
- P/E Ratio
- LZ $53.33
- MESO N/A
- Revenue Growth
- LZ 3.25
- MESO N/A
- 52 Week Low
- LZ $5.33
- MESO $5.78
- 52 Week High
- LZ $10.60
- MESO $22.00
- Technical
- Relative Strength Index (RSI)
- LZ 56.44
- MESO 40.85
- Support Level
- LZ $9.21
- MESO $10.60
- Resistance Level
- LZ $9.58
- MESO $11.26
- Average True Range (ATR)
- LZ 0.28
- MESO 0.41
- MACD
- LZ -0.02
- MESO -0.06
- Stochastic Oscillator
- LZ 16.55
- MESO 12.00
About LZ LegalZoom.com Inc.
LegalZoom.com Inc is an online provider of services that meet the legal needs of small businesses and consumers in the United States. The company also offers services that include ongoing compliance and tax advice and filings, business licenses, accounting, virtual mailbox and e-signature solutions, trademark filings, and estate plans.
About MESO Mesoblast Limited
Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.